Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed antidepressants. They can ease symptoms of moderate to severe depression, are relatively safe and typically cause fewer side effects than other types of antidepressants do.
With an increase in mental illnesses, there is a rising need for effective neurological drugs. Among the various neurological drugs available in the market, SSRIs drugs have high therapeutic efficacy. As a result, the number of vendors manufacturing these drugs is increasing. Moreover, health insurance companies, with support from governments, have started covering treatment expenses related to mental disorder. The rising prevalence of mental illnesses will significantly contribute to the selective serotonin reuptake inhibitors market growth.

Market Analysis and Insights: Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market
The global Selective Serotonin Reuptake Inhibitors (SSRIs) market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Selective Serotonin Reuptake Inhibitors (SSRIs) market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Selective Serotonin Reuptake Inhibitors (SSRIs) market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Selective Serotonin Reuptake Inhibitors (SSRIs) market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Selective Serotonin Reuptake Inhibitors (SSRIs) market.

Global Selective Serotonin Reuptake Inhibitors (SSRIs) Scope and Market Size
Selective Serotonin Reuptake Inhibitors (SSRIs) market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Selective Serotonin Reuptake Inhibitors (SSRIs) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Citalopram (Celexa)
Escitalopram (Lexapro)
Fluoxetine (Prozac)
Paroxetine (Paxil, Pexeva)
Sertraline (Zoloft)
Vilazodone (Viibryd)

Segment by Application
Depression
Anxiety and panic disorder
Other mental conditions

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Allergan Plc
Eli Lilly and Co.
GlaxoSmithKline Plc
H. Lundbeck AS
Pfizer Inc.